Literature DB >> 8255975

The relationship between serial measures of disease activity and outcome in rheumatoid arthritis.

A B Hassell1, M J Davis, P D Fowler, S Clarke, J Fisher, M F Shadforth, P W Jones, P T Dawes.   

Abstract

Disease activity was measured annually over a median period of 7 years (range 5-9) in a cohort of 127 patients with rheumatoid arthritis. The measurements were plotted, and the area under the resultant curve measured. The relationship of serial measures of disease activity (area under the curve) to outcome (measured radiologically, functionally and by global assessment) was investigated. A significant correlation was found between persistent disease activity and radiographic deterioration. Similar results were found for functional outcome, as measured by Steinbrocker grade, health assessment questionnaire score or global assessment (by analogue score). Single measures of disease activity did not predict outcome. Although imprecise, current methods of measuring disease activity in RA, if measured serially, are valuable in predicting outcome over a 5-10 year period.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8255975

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  10 in total

1.  The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

2.  Patients with rheumatoid arthritis in clinical care.

Authors:  J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

3.  Relative sialylation and fucosylation of synovial and plasma fibronectins in relation to the progression and activity of rheumatoid arthritis.

Authors:  Magdalena Przybysz; Dorota Maszczak; Krzysztof Borysewicz; Jacek Szechiński; Iwona Katnik-Prastowska
Journal:  Glycoconj J       Date:  2007-07-03       Impact factor: 2.916

4.  Association of polymorphism in glutathione S-transferase loci with susceptibility and outcome in rheumatoid arthritis: comparison with the shared epitope.

Authors:  D L Mattey; A B Hassell; M Plant; P T Dawes; W R Ollier; P W Jones; A A Fryer; J E Alldersea; R C Strange
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

Review 5.  Prognostic markers in rheumatoid arthritis and classification of antirheumatic therapies.

Authors:  E H Choy; D L Scott
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis.

Authors:  D L Mattey; N Nixon; P T Dawes; J Kerr
Journal:  Ann Rheum Dis       Date:  2005-02-04       Impact factor: 19.103

7.  Synovial membrane enhancement and bone erosion by magnetic resonance imaging for prediction of radiologic progression in patients with early rheumatoid arthritis.

Authors:  Nobuyuki Tanaka; Hisashi Sakahashi; Seiichi Ishii; Eiichi Sato; Kazuya Hirose; Takumi Ishima
Journal:  Rheumatol Int       Date:  2003-11-27       Impact factor: 2.631

Review 8.  Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments.

Authors:  E H Choy; D L Scott
Journal:  Drugs       Date:  1997-03       Impact factor: 11.431

9.  Patients with rheumatoid arthritis have an altered circulatory aggrecan profile.

Authors:  Jean C Rousseau; Eren U Sumer; Gert Hein; Bodil C Sondergaard; Suzi H Madsen; Christian Pedersen; Thomas Neumann; Andreas Mueller; Per Qvist; Pierre Delmas; Morten A Karsdal
Journal:  BMC Musculoskelet Disord       Date:  2008-05-28       Impact factor: 2.362

Review 10.  Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis-A Network Meta-Analysis of 36 Randomized Controlled Trials.

Authors:  Niels Graudal; Benjamin Skov Kaas-Hansen; Louise Guski; Thorbjørn Hubeck-Graudal; Nicky J Welton; Gesche Jürgens
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.